Targeting Mtors by Omega-3 Fatty Acids: A Possible Novel Therapeutic Strategy for Neurodegeneration? Publisher Pubmed



Shirooie S¹ ; Nabavi SF^{2, 3} ; Dehpour AR^{4, 5} ; Belwal T⁶ ; Habtemariam S⁷ ; Arguelles S⁸ ; Sureda A⁹ ; Daglia M¹⁰ ; Tomczyk M¹¹ ; Sobarzosanchez E^{12, 13} ; Xu S¹⁴ ; Nabavi SM³
Source: Pharmacological Research Published:2018

Abstract

Neurodegenerative diseases (NDs) such as Parkinson's (PD), Alzheimer's (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) cause significant world-wide morbidity and mortality. To date, there is no drug of cure for these, mostly age-related diseases, although approaches in delaying the pathology and/or giving patients some symptomatic relief have been adopted for the last few decades. Various studies in recent years have shown the beneficial effects of omega-3 poly unsaturated fatty acids (PUFAs) through diverse mechanisms including anti-inflammatory effects. This review now assesses the potential of this class of compounds in NDs therapy through specific action against the mammalian target of rapamycin (mTOR) signaling pathway. The role of mTOR in neurodegenerative diseases and targeted therapies by PUFAs are discussed. © 2018 Elsevier Ltd